These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 20377886)

  • 1. Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease.
    Melegaro A; Choi YH; George R; Edmunds WJ; Miller E; Gay NJ
    BMC Infect Dis; 2010 Apr; 10():90. PubMed ID: 20377886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.
    Weil-Olivier C; van der Linden M; de Schutter I; Dagan R; Mantovani L
    BMC Infect Dis; 2012 Sep; 12():207. PubMed ID: 22954038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study.
    Choi YH; Andrews N; Miller E
    PLoS Med; 2019 Jul; 16(7):e1002845. PubMed ID: 31269018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.
    Miller E; Andrews NJ; Waight PA; Slack MP; George RC
    Lancet Infect Dis; 2011 Oct; 11(10):760-8. PubMed ID: 21621466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data.
    Ojal J; Flasche S; Hammitt LL; Akech D; Kiti MC; Kamau T; Adetifa I; Nurhonen M; Scott JAG; Auranen K
    Vaccine; 2017 Aug; 35(35 Pt B):4561-4568. PubMed ID: 28729018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?
    Choi YH; Jit M; Gay N; Andrews N; Waight PA; Melegaro A; George R; Miller E
    PLoS One; 2011; 6(10):e26190. PubMed ID: 22022559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rise and fall of pneumococcal serotypes carried in the PCV era.
    Devine VT; Cleary DW; Jefferies JM; Anderson R; Morris DE; Tuck AC; Gladstone RA; O'Doherty G; Kuruparan P; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2017 Mar; 35(9):1293-1298. PubMed ID: 28161425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.
    Ladhani SN; Collins S; Djennad A; Sheppard CL; Borrow R; Fry NK; Andrews NJ; Miller E; Ramsay ME
    Lancet Infect Dis; 2018 Apr; 18(4):441-451. PubMed ID: 29395999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.
    Wagenvoort GH; Sanders EA; Vlaminckx BJ; de Melker HE; van der Ende A; Knol MJ
    Euro Surveill; 2017 Mar; 22(10):. PubMed ID: 28300529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.
    Andrews NJ; Waight PA; George RC; Slack MP; Miller E
    Vaccine; 2012 Nov; 30(48):6802-8. PubMed ID: 23000122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study.
    Flasche S; Van Hoek AJ; Sheasby E; Waight P; Andrews N; Sheppard C; George R; Miller E
    PLoS Med; 2011 Apr; 8(4):e1001017. PubMed ID: 21483718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
    Galanis I; Lindstrand A; Darenberg J; Browall S; Nannapaneni P; Sjöström K; Morfeldt E; Naucler P; Blennow M; Örtqvist Å; Henriques-Normark B
    Eur Respir J; 2016 Apr; 47(4):1208-18. PubMed ID: 26797033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
    van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E
    Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children.
    Tocheva AS; Jefferies JM; Rubery H; Bennett J; Afimeke G; Garland J; Christodoulides M; Faust SN; Clarke SC
    Vaccine; 2011 Jun; 29(26):4400-4. PubMed ID: 21504773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.
    Dagan R
    Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():16-20. PubMed ID: 19366365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.
    Gladstone RA; Jefferies JM; Tocheva AS; Beard KR; Garley D; Chong WW; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2015 Apr; 33(17):2015-21. PubMed ID: 25776920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.